Expert: Professor Michael Deininger Versiti Blood Research Institute, Milwaukee (USA)

Program:
Overview of significant biological aspects presented during the meeting, including:

• Abstract 1785: Loss of function of SETD2 tumor suppressor in chronic myeloid leukemia (CML) progenitors fosters genomic instability and enhances chronogenic potential (De Santi S et al.)
• Abstract 3151: Multiomic single-cell analysis identifies Van Willebrand factor and TIM3 expressing BCR-ABL1 chronic myeloid leukemia stem cells (Nilsson MS et al.)
• Abstract 449: Impact of mutations in blood cancer-related genes on clinical outcomes in chronic myeloid leukemia in chronic phase (CML-CP) after ≥ tyrosine kinase inhibitors (TKIs) in the Ascembl trial (Branford S et al.)
• Abstract 862: Nutrient-sensitising drug repurposing screen identifies Lomerizine as a mitochondrial metabolism inibitor in chronic myeloid leukemia (Khalaf A et al.)
• Questions and Answers

If you have any questions or comments to the speaker, please email info@cml-foundation.org.

Timestamps:

00:00 Introduction
01:28 Abstract 1785: Loss of function of SETD2 tumor suppressor in chronic myeloid leukemia (CML) progenitors fosters genomic instability and enhances chronogenic potential (De Santi S et al.)
02:35 Abstract 3151: Multiomic single-cell analysis identifies Van Willebrand factor and TIM3 expressing BCR-ABL1 chronic myeloid leukemia stem cells (Nilsson MS et al.)
04:24 Abstract 449: Impact of mutations in blood cancer-related genes on clinical outcomes in chronic myeloid leukemia in chronic phase (CML-CP) after ≥ tyrosine kinase inhibitors (TKIs) in the Ascembl trial (Branford S et al.)
12:03 Abstract 862: Nutrient-sensitising drug repurposing screen identifies Lomerizine as a mitochondrial metabolism inibitor in chronic myeloid leukemia (Khalaf A et al.)
19:48 Questions and Answers
25:17 Thanks and Conclusion